| 2016 | Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
| ONCOTARGET |
| 2019 | Next-generation sequencing with comprehensive bioinformatics analysis facilitates somatic mosaic APC gene mutation detection in patients with familial adenomatous polyposis
| BMC Medical Genomics |
| 2008 | NFkappaB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions.
| PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA |
| 2021 | Nicotine Dependence and Stress Susceptibility in E-Cigarette Smokers: The Korea National Health and Nutrition Examination Survey 2013-2017
| TUBERCULOSIS AND RESPIRATORY DISEASES |
| 2013 | Nine-Month Angiographic and Intravascular Ultrasound Outcomes After Resolute Zotarolimus-Eluting Stent Implantation for the Treatment of In-Stent Restenosis | JOURNAL OF INTERVENTIONAL CARDIOLOGY |
| 2006 | Nine-year survival of lymphoblastic lymphoma patients
| YONSEI MEDICAL JOURNAL |
| 1997 | Nitinol Self-Expanding Stents: When Severe Twisting Occurs, Self-Expansion May Ensue After a Waiting Period | ENDOSCOPY |
| 2022 | Nitrates vs. Other Types of Vasodilators and Clinical Outcomes in Patients with Vasospastic Angina: A Propensity Score-Matched Analysis
| JOURNAL OF CLINICAL MEDICINE |
| 1997 | Nitric Oxide와 Vasoactive Intestinal Peptide가 기니 픽 위저부 평활근 이완에 미치는 영향
| Korean Journal of Gastroenterology |
| 2022 | Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722 | ANNALS OF ONCOLOGY |
| 2021 | Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
| JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma | NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
| Journal of Liver Cancer (대한간암학회지) |
| 2018 | Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
| LUNG CANCER |
| 2015 | Nivolumab in NSCLC: latest evidence and clinical potential | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | LANCET |
| 2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
| GASTRIC CANCER |
| 2022 | Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial | LANCET ONCOLOGY |
| 2019 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | LANCET ONCOLOGY |
| 2021 | Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
| ANNALS OF ONCOLOGY |
